Dr. Deepak Bhamidipati
Hematology & Oncology (Hematology & Oncology Physician)
At a glance
- Years since graduation
- 8
- In the NPI registry since
- 2018
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2018Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TN license 72503 - Student in an Organized Health Care Education/Training Program
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Tristar Centennial Medical Center Nashville, TN
- Tristar Summit Medical Center Hermitage, TN
- Tristar Skyline Medical Center Nashville, TN
- Tristar Southern Hills Medical Center Nashville, TN
Medical groups
- Verdi Oncology Tennessee PC (31 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 25 companies reported 66 payments worth $1,437 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $188 |
|---|---|
| Daiichi Sankyo Inc. | $170 |
| E.r. Squibb & Sons, L.l.c. | $141 |
| Array Biopharma Inc | $133 |
| Regeneron Healthcare Solutions, Inc. | $120 |
| Merck Sharp & Dohme LLC | $98.70 |
| Celgene Corporation | $71.67 |
| Springworks Therapeutics, Inc. | $66.17 |
| Food and Beverage | $1,437 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $433 in research payments for these studies, mostly to the institutions running them.
- A Phase 1/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic S…
Amgen Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.